Pliant Therapeutics, Inc.

NasdaqGS PLRX

Pliant Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 66.96%

Pliant Therapeutics, Inc. Gross Profit Margin is 66.96% for the Trailing 12 Months (TTM) ending September 30, 2024, a 430.62% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Pliant Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -20.25%, a -139.34% change year over year.
Pliant Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 51.49%, a -46.38% change year over year.
Pliant Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 96.02%, a -3.98% change year over year.
Pliant Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 100.00%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGS: PLRX

Pliant Therapeutics, Inc.

CEO	Dr. Bernard Coulie M.B.A., M.D., Ph.D.
IPO Date	June 3, 2020
Location	United States
Headquarters	260 Littlefield Avenue
Employees	166
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key trends

Past 5 years